Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MANE vs SYRE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SYRE Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 8–0 Matrix Metrics)

SYRE Overall Winner 6-Pillar Tally: MANE 1 – 2 SYRE (3 Tie) Matrix Metrics: MANE 0 – 8 SYRE

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MANE carries a Unified Composite Score of 38.1/100 (SELL) at $128.03 (N/M Forward P/E, N/A operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.60 (N/M Forward P/E, 0.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MANE vs SYRE
MANE US Equity
MANE
Institutional Equity
$128.03
-1.26% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.28β · 80% Vol
Unified Composite Score
38.1 / 100 SELL
Tech 15.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $137.77 · SMA50: $122.82
SYRE NASDAQ Head-to-Head Winner
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.60
-4.23% 1D
Market Cap $9.8B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 58% Vol
Unified Composite Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.5 · SMA20: $98.78 · SMA50: $91.70

6-Pillar Scorecard Institutional Category Breakdown (MANE 1 – 2 SYRE)

Columns: Metric · MANE · SYRE
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale SYRE
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A -99.7%
TTM Revenue (USD) N/A N/A
Market Cap N/A $9.8B
3. Profitability & Quality SYRE
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -35.0%
4. Balance Sheet & Cash Flow MANE
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $10.06 Book/Sh · -35.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 87.9% (10th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MANE (0) vs SYRE (8)
Institutional Metric MANE SYRE Criterion Row Edge
Market Capitalization
Scale
N/A $9.8B Larger Scale SYRE
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth SYRE
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin SYRE
Net Profit Margin
Profitability
N/A 0.0% Higher Margin SYRE
Return on Equity (ROE)
Capital Efficiency
N/A -35.0% Higher ROE SYRE
52-Week Range Position
Momentum
77% ($32–$157) 88% ($22–$111) Stronger Trend SYRE
Beta / 30D Volatility
Risk Regime
1.28β · 80% Vol 1.74β · 58% Vol Lower Realized Risk SYRE
Unified Institutional Score
Composite Signal
38.1 / 100 (SELL) 44.4 / 100 (HOLD) Higher Composite SYRE
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A ($10.06 Book/Sh · -35.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SYRE +7.01 pp
MANE: +17.65% · SYRE: +24.66%
3M Horizon MANE +22.64 pp
MANE: +15.02% · SYRE: -7.62%
6M Horizon SYRE +14.57 pp
MANE: +27.55% · SYRE: +42.12%
1Y Horizon MANE +28.58 pp
MANE: +239.15% · SYRE: +210.57%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MANE vs SYRE. Trailing 12-month operating profitability (MANE N/A vs SYRE 0.0%) and valuation multiples (MANE N/M vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MANE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
SYRE ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-35.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MANE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MANE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 87.9%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SYRE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MANE Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SYRE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.8B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MANE vs SYRE Key Questions & Quantitative Answers

As of Nov 16, 2026, Spyre Therapeutics, Inc. (SYRE) is the stronger overall head-to-head candidate over MANE (MANE) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). MANE carries a Unified Composite Score of 38.1/100 (SELL) at $128.03 (N/M Forward P/E, N/A operating margin), whereas SYRE carries 44.4/100 (HOLD) at $99.60 (N/M Forward P/E, 0.0% operating margin). Technically, MANE sits in a Neutral phase (RSI 47.0, UNCLASSIFIED options structure) and SYRE sits in a Neutral phase (RSI 53.5, UNCLASSIFIED options structure).

SYRE leads the Growth & Scale pillar: MANE posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with SYRE at +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MANE generates N/A in USD-normalized revenue versus N/A for SYRE. In operating R&D and SG&A reinvestment, MANE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SYRE.

MANE and SYRE trade at balanced relative valuation multiples. MANE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MANE (N/A ROE) versus SYRE (-35.0% ROE) capital efficiency.

In options market volatility and institutional positioning, MANE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.28β · 80% Vol realized risk). By comparison, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 58% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.